The functional signals were limited
A randomized, blinded trial studied oral NMN in healthy older men for six or twelve weeks. Blood NAD-related measurements increased. The authors reported nominally significant improvements in gait speed and the left-hand grip test, but no significant body-composition effect. They said the functional findings require validation in larger studies. [1]
The published participant-flow description states that forty-two men were randomized, with a protocol deviation affecting twenty-two participants after the six-week visit; twenty completed the twelve-week study. That detail matters when interpreting later measurements. It should not be summarized as forty-two people providing a full twelve-week comparison. [1]
Why “nominally significant” should stay in the sentence
The qualifier signals that a favorable statistical result needs context, including the number of comparisons and the analysis plan. Removing it can turn a preliminary finding into an apparently definitive one. Ask whether the result remained convincing under the study’s full statistical framework.
The left-hand detail is also relevant. A favorable finding in one grip measurement should not become a general promise of stronger muscles. The reader needs to know which test changed, which did not and whether the observed difference would matter in everyday life.
Likewise, unchanged body composition should remain beside the functional signals. Strength, walking speed and muscle mass are related interests, but they are distinct outcomes. A study can generate different answers for each.
Participant flow is part of the evidence
A trial’s enrollment number is often the largest and most visible number in a marketing summary. The number available for a particular analysis may be smaller. Reading the flow diagram helps distinguish randomization, follow-up and the actual dataset behind a result.
A protocol deviation is not automatically evidence that a study is worthless. It is a reason to inspect how researchers handled the affected observations and how the limitation changes confidence. A transparent summary should tell the reader that the issue exists.
The sixty-person older-adult trial offers a different functional design with a null primary endpoint and some favorable secondary findings. Compare the named tests rather than combining every positive phrase into a claim that NMN reverses muscle aging.
This study supports further work on physical function in a defined older-male population. It does not establish sarcopenia treatment, a retail-product ranking or a personal exercise benefit. Our exercise evidence article helps place these findings alongside other functional outcomes without assuming that endurance, grip strength and gait are interchangeable. For each functional graph, identify the number analyzed at that visit rather than assuming the initial enrollment supplied every later measurement.